1,350,000 Shares in Pfizer Inc. $PFE Purchased by Tredje AP fonden

Tredje AP fonden acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,350,000 shares of the biopharmaceutical company’s stock, valued at approximately $33,615,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new position in Pfizer during the third quarter valued at $3,019,000. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Pfizer in the third quarter worth $16,613,000. Money Concepts Capital Corp grew its stake in shares of Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Penn Davis Mcfarland Inc. increased its holdings in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. CICC Research assumed coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.84.

Pfizer Price Performance

NYSE PFE opened at $25.31 on Tuesday. Pfizer Inc. has a one year low of $22.64 and a one year high of $28.75. The stock has a 50-day moving average of $26.96 and a 200 day moving average of $26.20. The company has a market capitalization of $144.22 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.